Introduction
A new transient form of hyperphenylalaninemia is characterized by the excretion of 7-substituted pterins in urine of patients, e. g. the 7-L-analogue of L-biopterin (L-primapterin), the 7-D-or L-analogue of Dneopterin (D-or L-anapterin), and 6-oxo-7-L-or Danalogue of 7-oxo-L-biopterin (6-oxo-L-or D-primapterin) (1, 2).
The structure elucidation of the 7-substituted pterins was performed using GC-MS, oxidation to their 7-carboxylic acids, and comparison with reference substances (1, 3) . The determination of the absolute configuration of excreted primapterin belonging to the L-series like its 6-analogue was done by CD-measurement (4). Both, L-primapterin and D-or L-anapterin were identified in control urines, blood and in liver of man and mouse (3, 5) , but only in very small amounts.
The excretion of 7-substituted pterins seems to be associated with an enzyme defect in the aromatic amino acid hydroxylating system. In vivo formation of 7-substituted pterins was achieved incubating their fully rcduced 6-analogues with pterin-4a-carbinolaminc dehydratase-free rat or human phenylalanine hydroxylase (6, 7) . It was concluded that the patients most probably suffer from a pterin-4a-carbinolamine dehydratase (PCDH) deficiency (6) .
From the finding that in vitro the 7-D-or L-analogue of D-neopterin originates from its 6-tetrahydro analogue by incubating D-NH 4 with dehydratase-free phenylalanine hydroxylase, one might speculate that in vivo D-tetrahydroncopterin also acts as cofactor for the pterin dependent aromatic amino acid hydroxylases. This might be the reason for the occurrence of D-or L-anapterin in the urine of patients and controls.
In this study we show that D-NH 2 is a substrate for DHFR and can be transformed to D-NH 4 which possibly could also be a cofactor for the aromatic amino acid hydroxylases in vivo. Further we provide direct GC-MS evidence for the structure of in vitro formed L-primapterin. We could give an explanation for the hyperphenylalaninemia of these primapterinuric patients.
Methods
Pterins were oxidized with manganese dioxide under acidic conditions [8] , They were analyzed by reversephase HPLC with fluorescence detection (excitation/ emission wavelengths were 350/450 nm). Inhibition experiments with dehydratase-free rat liver phenylalanine hydroxylase were performed in 0.1 M Tris-HCl, with 0.35 U phenylalanine hydroxylase (specific activity 8.5 U/mg protein), 1 mM L-phenylalanine, and an excess of both catalase and DHPR, 5 mM NADH, Ltetrahydrobiopterin (L-BH 4 ) as substrate (concentrations from 5 to 20 μΜ) and L-tetrahydroprimapterin as potential inhibitor (concentrations from 2 to 30 μΜ). For GC-MS measurements of the in vitro formed L-primapterin we used a VG-Ì6F single-focusing magnetic-field instrument according to the method of Küster et al. (9) .
Results and Discussion

Structure elucidation of in vitro formed L-primapterin
The identiy of L-primapterin was confirmed by GC-MS as TMS derivative. For GC a glass capillary column was used. Under the GC conditions used the silyl derivatives of the two isomers are clearly separated (see Fig. 1 ).
The mass spectra of both peaks were essentially identical and were confirmed using chemically synthesized L-biopterin and L-primapterin. The signal at m/z 409 corresponds to the pterin nucleus (Fig. 1) when the Y-2' bond of the L-primapterin side-chain is cleaved and a proton of the 3'-methyl group shifts to the 6-position of the pyrazine ring [9] . GC-MS data obtained of in vitro formed L-primapterin give conclusive evidence for the proposed structure.
Inhibition of phenylalanine hydroxylase
The reason for transient hyperphenylalaninemia of primapterinuric patients has for a long time been a puzzling problem. L-tetrahydroprimapterin might inhibit phenylalanine hydroxylase activity, resulting in an increase of plasma phenylalanine. We showed that L-tetrahydroprimapterin competes with L-BH 4 for the active site of the enzyme (Fig. 2) . The K¡ value of 8 μΜ obtained for L-tetrahydroprimapterin compares to K m values of 20 μΜ and 1.5 μΜ, respectively, for L-tetrahydroprimapterin and L-BH 4 as substrates. This observation strongly suggests that in these patients phenylalanine hydroxylase is inhibited by their own abnormal metabolites, the 7-substituted tetrahydropterins, resulting in hyperphenylalaninemia.
The group of Davis et al. (10) states another reason for the hyperphenylalaninemia of these patients: Ltetrahydroprimapterin might be an inefficient cofactor of the phenylalanine hydroxylase and the oxidation of the pterin cofactor would not be coupled to the amino acid hydroxylation.
Nevertheless, primapterinuric patients excrete less L-BH 4 compared to controls (about 40% of urinary Lbiopterin in tetrahydroform compared to 60 -80% in controls). Still, there should be enough cofactor present, especially because regeneration of cofactor with DHPR was not found to be inhibited by 7-substituted pterins. 
D-Tetrahydroneopterin as cofactor in vivo
As the 7-D-or L-isomer of D-neopterin is also excreted in the urine of primapterinuric patients as well as in control urine one can speculate that other tetrahydropterins than L-BH 4 temporarily act as cofactors and that the need for them varies at different stages of development. A metabolic intermediate in BH 4 biosynthesis is D-tetrahydroneopterin triphosphate a compound that is present in substantial concentrations in body fluids. The phosphate group can be hydrolysed by the action of phosphorylases. DHFR, which accepts a variety of substrates, may also reduce D-NH 2 to its biologically active tetrahydroform. In vitro we found substantial concentrations of D-tetrahydroneopterin after incubation of D-dihydroneopterin with dihydrofolate reductase in vitro.
Since in vitro D-tetrahydroneopterin is a cofactor of phenylalanine hydroxylase, and in spite of the fact that the activity is only 20% compared with L-BH 4 , this pterin might play an important role in patients with 6-pyruvoyl tetrahydropterin synthase deficiency. These patients excrete increased amounts of D-neopterin but very low levels of L-biopterin D-tetrahydroneopterin might thus act as cofactor for the aromatic amino acid hydroxylases. Here we might have an explanation for the finding that these patients have low but nevertheless substantial levels of the neurotransmitters deopamine and serotonin in tissues and bodyfluids.
